A recent experience of the senior author when addressing a meeting of anaesthetists prompted this review, since it was apparent that there was still considerable disagreement between hepatologists and anaesthetists over the association between liver cell damage and halothane anaesthesia and the measures by which the risk could be minimised. Although during the 1960s and 1970s the evidence was hotly debated, there has since been increasing acceptance, both clinical and experimental, of a strong prima facie case for an association.'" Two, probably distinct, forms of liver damage have been defined.'2 Serum aminotransferase activities are raised in up to a fifth of patients anaesthetised with halothane during the first and second postoperative weeks (type I). Such minor forms of liver injury are to be distinguished from the rare occurrence of massive liver cell necrosis (type II).
aminotransferase (AST) activity during the postoperative period were found only in those patients receiving halothane,5 and these activities were significantly higher than in those receiving trichloroethylene. 6 Abnormalities in liver function were not always apparent until the second postoperative week. Rises of serum amunotransterase activity were also greater in those receiving halothane than with enflurane,8 and obese women were more likely to develop abnormalities.
Most patients who have developed massive necrosis have had a previous and milder reaction to halothane. Nevertheless, the frequency of minor abnormalities (up to 20%) and the very low incidence of massive necrosis make it clear that minor reactions are not necessarily followed by more severe effects. There is no way of predicting which patients will follow this course.
We have seen now 48 patients with otherwise unexplained massive liver cell necrosis after halothane anaesthesia referred to the liver unit over the period January 1965 to December 1983. In each of the 48 patients other possible causes of liver damage were excluded, including exposure to hepatotoxic agents, sepsis, hypotension during surgery, and infection with hepatitis A and B, cytomegalovirus, and Epstein-Barr virus. In no case was there evidence of pre-existing liver disease.
Thirty one of the 48 patients were women, giving a female to male ratio of 1 8:1. Ages ranged from 21 
Pbtients (i/)
In all cases hepatic encephalopathy had developed within 28 days of the exposure to halothane (median nine days).
Of the 48 patients, 45 (94%) were known to have been exposed to halothane on at least one previous occasion, 24 (50%) had had two or more previous exposures, and four (8-5%) had been exposed three or more times. Of those who had received halothane on more than one occasion, the penultimate exposure was within a period of four weeks in 27 patients and one to two months in six patients. In only three was the penultimate exposure more than one year previously (two, six, and seven years). The shorter the interval between the most recent two exposures the more rapid was the
transferase activities returned to normal. Liver biopsy specimens taken on two occasions when serum aminotransferase activities were raised showed features of acute hepatitis. For the past eight years this surgeon has avoided halothane exposure and has remained healthy, with normal liver function tests. In both patients specific "halothane antibody" was present. 13 Occupational exposure to halothane is likely to result in the induction of hepatic enzymes,20 and the effect of this on halothane biotransformation in susceptible individuals may be important. A positive challenge has been carried out in three patients but is not recommended because of the risk of inducing a more severe reaction.
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In over two thirds (33 patients (69%)) the surgery was relatively minor (defined as lasting less than 30 minutes), the majority of these being gynaecological intervention-usually dilatation and curettage-eye surgery, or wound dressing. Of the 15 patients undergoing major surgery, five had had a laparotomy, three a hysterectomy, and two biliary tract surgery. Postoperative fever for which no other specific cause could be identified was recorded in 36 (75%) patients. Serum autoantibodies (antiliver kidney microsomal, antismooth muscle, and antinuclear) were found during the course of the liver failure in 21 (44%) of the patients.
Thirty eight of the 48 patients died, in each instance after conscious levels had deteriorated to grade III or IV hepatic encephalopathy, and with a clinical course similar to that seen with other causes of fulminant hepatic failure.'4 Five of the 10 patients who survived had less severe encephalopathy (grades I and II) and all ultimately made a complete recovery. The duration of illness in those who died was 11 to 73 days (median 23 
days).
Liver damage after occupational exposure to halothane has been reported in surgeons, anaesthetists, and operating theatre personnel.'3-' We have described two surgeons who developed abnormalities of liver function, in one of whom rises in serum aminotransferase activities were noted on four occasions, each time related to halothane." With avoidance of exposure serum amino-A severe, idiosyncratic reaction is characteristically found after multiple anaesthetics (up to 10 times more frequently than that after a single exposure), often for relatively minor surgery, and the shorter the interval between successive halothane exposures the more rapid the onset of liver damage. Serological abnormalities indicative of hypersensitivity include peripheral eosinophilia and serum autoantibodies (notably the liver-kidney microsomal antibody), as well as circulating immune complexes.7 111421 Obese women appear to be particularly susceptible, and some series have shown a significant frequency of eczema and drug allergy.7 10 II The availability of specific serological tests for detection of hepatitis A and B has allowed these other causes of fulminant hepatic failure to be excluded with greater certainty. In addition, we have recently described a specific serum antibody which reacts with halothane altered liver cell determinants,22 thus providing a positive means of 122. identification .2a
Mechanisms of hepatotoxicity
The idiosyncratic reaction to halothane may be due to (a) enhanced metabolism of the drug through a minor pathway with the development of reactive metabolites, or (b) an immune response to "new" antigens. We showed sensitisation to halothane altered liver cell membranes in eight of 16 consecutive patients admitted during 1979 and 1980 with fulminant hepatic failure after halothane anaesthesia.48 IgM class antibodies to the hepatitis A virus were present in four of the patients with negative test results, only one of whom had been exposed to halothane on more than one occasion. (All those with the halothane antibody had been exposed two or more times.) Halothane anaesthesia may exacerbate a preexisting, but mild, hepatitis A infection. One of the other four patients had received seven units of blood at the first operation, raising the possibility of a non-A, non-B viral hepatitis; another was receiving rifampicin and isoniazid, whose toxicity may have been potentiated by halothane.4' The clinical and biochemical features of patients with and without sensitisation to halothane altered cell determinants are no different, so that our failure to show sensitisation may be due to absorption of antibody by hepatocytes, or to its presence as immune complexes.' The time at which samples are obtained is also important: antibodies cease to be detectable in the serum as the clinical condition deteriorates.
Specific antibodies reacting with halothane altered liver cell membranes have been shown by indirect immunofluorescence and induced cytotoxicity techniques22 and confirmed by an enzyme linked immunosorbent assay. A subpopulation of normal lymphocytes (K cells) is used to bind to and lyse antibody coated target cells. Antibody specificity is such that it cannot be shown in patients with liver damage from other causes, patients exposed to multiple halothane anaesthetics without liver damage, or anaesthetists with normal liver function. The antibody persists for at least six months in those patients who survive fulminant hepatic failure (Neuberger, unpublished data). Its development is unlikely to be a secondary response to liver cell damage, as selective second antibodies in the indirect immunofluorescence assay showed the presence of IgM antibodies (which would be expected with a primary immune response) in only two patients. Furthermore, the antibody has not been shown in those patients who, after being given halothane, developed necrosis from other causes, such as sepsis, hvpotension, or carcinomatous infiltration of the liver.
Even though the antibody may induce K cell mediated cytotoxicity in vitro, the importance of this reaction in the pathogenesis of liver damage in vivo has to be determined"'; how halothane exposure results in the generation of a new antigen has not been established. Anaesthetic agents alter the character of liver cell membranes,"' but it is unlikely that the appearance of the antigen is due to a direct effect on the membrane. The antigen is not present on the membrane immediately after the animal has been exposed to halothane (Neuberger, 20 million people, and the validity of some of the reported cases of hepatotoxicity has been questioned. 53 Isoflurane has yet to be definitely implicated.
The clinical picture is similar to that seen with halothane hepatotoxicity. There is a higher incidence in those exposed previously, and the Qnset of jaundice occurs sooner after multiple exposures than after a single exposure. A similar proportion of patients have allergy (15-21%), unexplained fever (50-79%), and eosinophilia (20-50%). A rash occurs in 5-12%. Mortality from enflurane hepatotoxicity is 21% compared with 58% for methoxyfiurane and about 50% for halothane.54 It may be relevant that, like halothane, methoxyflurane undergoes considerable biotransformation in man in contrast to the minimal change of enflurane and the almost nil change of isoflurane. There are, however, cases of cross reactivity between halothane and enflurane and isoflurane. 9 and 19 respectively. Such figures are affected by the interest of the medical community (and acceptance of the association between the two) at any one time, and we would question from our own experience whether there has been such a sharp drop. Halothane may cause both minor and occasionally massive hepatocellular injury. The major risk factor for the latter is repeated exposure to the agent. In 1978 Inman and Mushin,'0 after an analysis of all reported cases in England, recommended that halothane anaesthesia should not be repeated within a short period, and the advice is incorporated in the data sheets. In spite of this just over half the patients seen by us since then have been exposed to halothane twice within four weeks. Some 60% of patients in whom adequate data were available had had a documented adverse reaction to halothane previously, and care should be taken in examining case records, as information from the patient may be misleading.
Two groups of patients need special consideration before halothane is used. Firstly, those who are likely to require multiple anaesthetics within a short period should not be given halothane more than once; other anaesthetic agents should be considered for subsequent operations. Secondly, those who may be at greater risk because of factors such as female sex, obesity, and a history of allergy should be carefully assessed, especially if more than one exposure is likely. If a patient develops unexplained abnormalities of liver function after halothane the information should be stamped on the front of the case records and the patient informed. Both actions may ensure that the anaesthetist can be properly alerted if further anaesthesia becomes necessary.
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